Investor Area

Home / Investor Area / News / CEO Brief – January 20, 2016

CEO Brief – January 20, 2016

20 January 2016

 

Having both received and provided services within the healthcare sector over the years I am all too aware of the peril of compromised health and loss of your livelihood. In Clinuvel’s case we aspire to make our patients realise their dreams and ambitions by making SCENESSE® (afamelanotide 16mg) available to all erythropoietic protoporphyria (EPP) patients and, in time, to vitiligo patients. Once this important goal is achieved we will be able to look back at a long and successful but challenging journey, being thankful that we have been able to maintain our physical and mental wellbeing throughout the process. I wish all of you who have supported us a year in bonne santé

 

Download PDF for more